Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad ...

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight ...

Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...

The latest price target for Voyager Therapeutics (NASDAQ:VYGR) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $12.00 expecting VYGR to rise to within ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...